{"entity":{"id":"cdk-inhibitor-payloads","kind":"term","name":"Cyclin-dependent kinase inhibitor payloads","aka":["CDK inhibitor payloads","CDK2/7/9 inhibitor conjugates","SNS-032 payload","CDK9 inhibitor payloads"],"tldr":"These payloads block enzymes that help cells divide or read genes. An antibody may help deliver them to cancer cells that depend on those processes.","summary":"A cetuximab conjugate carrying SNS-032 was tested in EGFR-expressing triple-negative breast cancer cells, spheroids and xenograft models. SNS-032 inhibits CDK2, CDK7 and CDK9; it should not be described as a selective CDK9 payload. The study supports preclinical cell-cycle-directed delivery. A CDK inhibitor payload is also different from a degrader payload that removes a CDK protein.","asOf":"2026-11-08","links":[{"label":"Cetuximab-SNS-032 in breast cancer models (2024)","url":"https://doi.org/10.1158/1078-0432.CCR-23-3110"}],"tags":[],"related":["transcription-inhibitor-payloads"],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["payload"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"ADC chemistry"},"route":"/terms/cdk-inhibitor-payloads/","neighbours":{"term":[{"id":"next-generation-adc-payloads","kind":"term","name":"Next-generation antibody-conjugate payloads","route":"/terms/next-generation-adc-payloads/"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/"},{"id":"transcription-inhibitor-payloads","kind":"term","name":"Transcription-inhibitor payloads","route":"/terms/transcription-inhibitor-payloads/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}]}}